Evidence Table 2. Assessment and Monitoring: Usefulness of Peak Flow Measurement

Abbreviations used in table:

BA	**beta-agonist**	**MIC**	**methacholine inhalation challenge**
BI	**basic information**	**NEB**	**nebulizer**
CI	**confidence interval**	**NPV**	**negative predictive value**
COPD	**chronic obstructive pulmonary disease**	**PEF**	**peak expiratory flow**
ED	**emergency department**	**PEFR**	**peak expiratory flow rate**
EI	**extended information**	**PFM**	**peak flow meter/monitoring**
FEV_1	**forced expiratory volume in 1 sec**	**PL**	**placebo**
$FEF_{25–75\%}$	**forced expiratory flow between 25% and 75% of the vital capacity**	**r_c**	**concordance correlation coefficient**
FRC	**functional residual capacity**	**ROC**	**receiver operating characteristic**
ICS	**inhaled corticosteroid**	**RV**	**residual volume**
IQR	**interquartile range**	**TLC**	**total lung capacity**
MDI + S	**metered-dose inhaler with spacer**		

*** indicates primary outcome**

Evidence Table 2. Assessment and Monitoring: Usefulness of Peak Flow Measurement

Citation (Sponsor)	Study Design	Study Population		
		Study N (Number Evaluable)	Population Characteristics	Asthma Severity at Baseline (if reported)
A. Validity/Correlation of PEF				
Alcock et al. Symptoms and pulmonary function in asthma. Respir Med 1998;92(6):849–857. (National Asthma Campaign, GlaxoWellcome, Breathe North, and Duncan Flockhart)	Longitudinal descriptive study	824	**Age** >18 yr, mean = 55 yr **Gender** 49% male, 51% female **Smoking** 7.5% current smokers 40.3% never smokers	Best PEF, mean = 94.5% Actual/best PEF, mean = 87.5% Best FEV_1 % pred., mean = 84.6% Actual/best FEV_1 % pred., mean = 89.6 22.5% had nocturnal disturbance 46.3% had persistent daytime symptoms
Brand et al. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyper responsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax 1999;54(2):103–107. (Netherlands' Government Health Research Promotion Programme)	Multicenter, randomized, double-blinded trial	116	**Age** 7–14 yr, mean = 11 yr **Gender** 74% male, 26% female	FEV_1 % pred., mean = 79 PD_{20}, geometric mean = 18.4 mcg Morning PEF, mean = 281 L/min Afternoon PEF, mean = 305 L/min Diurnal PEF variation, mean = 13.7%
Eid et al. Can peak expiratory flow predict airflow obstruction in children with asthma? Pediatrics 2000;105(2):354–358.	Observational (descriptive)	244 (357 sets of pulmonary function tests)	**Age** 4–18 yr, mean = 10.2 yr **Gender** 56.1% male, 43.9% female **Ethnicity** 79.4% White 20.6% other	Moderate-to-severe asthma PEF, range 27–174, mean = 79.4 FEV_1, % pred., range 28–134, mean = 82.9 $FEF_{25–75\%}$, range 10–158, mean = 70.3 RV/TLC, range 10.6–66.6, mean = 30.2 RV, range 38–371, mean = 136.7 FRC, range 50–192, mean = 105.3

Citation (Sponsor)	Study Design	Study Population		
		Study N (Number Evaluable)	Population Characteristics	Asthma Severity at Baseline (if reported)
Goldstein et al. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001;119(4): 1001–1010. (Asthma Center Education and Research Fund; Merck & Cos., Inc.)	Prospective descriptive study	121 (57)	**Age** 30% 7–18 yr, 70% >18 yr	At least 3 months with asthma-like symptoms FEV_1 % pred. $\geq$80% $FEF_{25–75\%}$ $\geq$80% FVC % pred. $\geq$80%
Kamps et al. Peak flow diaries in childhood asthma are unreliable. Thorax 2001;56(3):180–182.	Prospective randomized controlled trial	40 (40)	**Age** 5–16 yr, mean = 9.2 yr **Gender** 61.5% male, 32.5% female	Moderately severe persistent asthma Clinically stable on inhaled corticosteroid (ICS), mean dose = 268 mcg FEV_1 % pred., mean 103.5
Leone et al. The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical research. Chest 2001;119(4):1027–1033. (National Institutes of Health)	Secondary analysis of data from 2 ACRN studies: $Beta_2$-Agonists in Mild Asthmatics study and Colchicine in Moderate Asthma study	326 (313)	**Age** 13–58 yr, mean = 30.2 yr **Gender** 44% male, 56% female **Ethnicity** 33% minority	78% mild asthma, 22% moderately severe FEV_1, mean = 3.01 L FEV_1 % pred., mean = 87 PEF, mean = 415 L PEF % pred., mean = 91
Llewellin et al. The relationship between FEV_1 and PEF in the assessment of the severity of airways obstruction. Respirology 2002;7(4):333–337. (Health Research Council of New Zealand; the Guardian Trust)	Retrospective study using medical records	101 (2,587 paired measurements)	**Age** 18–70 yr, mean = 38.4 yr **Gender** 56% male, 44% female	55% with clinical diagnosis of asthma; 45% with clinical diagnosis of chronic obstructive pulmonary disease (COPD) Number of visits to clinic ranged from 2 to 171 with median of 4 FEV_1 % pred., range 15–124, mean = 55 at median visit

Citation (Sponsor)	Study Design	Study Population		
		Study N (Number Evaluable)	Population Characteristics	Asthma Severity at Baseline (if reported)
Reddell et al. When can personal best peak flow be determined for asthma action plans? Thorax 2004;59(11):922–924. (Asthma Foundation of NSW, the National Health and Medical Research Council of Australia, AstraZeneca Sweden and AstraZeneca Australia)	Secondary analysis of data from a 72-week randomized trial (high-dose budesonide study)	61 subjects; 42,590 spirometric maneuvers	**Age** 18–75 yr **Gender** Not reported **Smoking** All nonsmokers	Poorly controlled asthma with ICS up to 1,200 mcg/day Reliever use, mean 3 occasions/day (IQR 1.9 to 4.4) Morning PEF, mean 340 L/min (61% predicted, 95% CI 57 to 66) Within-session PEF reproducibility 19 L/min (IQR 14–25)
B. Peak flow versus symptoms in management				
Adams et al. A randomized trial of peak-flow and symptom-based action plans in adults with moderate-to-severe asthma. Respirology 2001;6(4):297–304. (The University of Adelaide, The Queen Elizabeth Hospital Research Foundation)	Prospective, randomized controlled trial	172 (134)	**Age** >16 yr, mean = 36.5 yr **Gender** 39% male, 61% female	Moderate-to-severe asthma Duration of asthma, mean = 13.9 yr FEV_1 % pred., mean = 75.7 Inhaled steroids, mean = 746 mcg/day 73% taking both ICS and bronchodilators; 22% using bronchodilators only; 5% no asthma medications 56% hospitalized in past year 60% ED visit in past year

Citation (Sponsor)	Study Design	Study Population		
		Study N (Number Evaluable)	Population Characteristics	Asthma Severity at Baseline (if reported)
McMullen et al. Peak flow meters in childhood asthma: parent report of use and perceived usefulness. J Pediatr Health Care 2002;16(2): 67–72. (National Institutes of Health)	Randomized clinical trial	168 (136 at 1 year)	**Age** 74% school-aged, 26% adolescent **Gender** 59% male, 41% female **Ethnicity** 66% White 24% Black 10% other **Socioeconomic Status** 51% upper 49% lower **Geographic Location** 34% urban 66% nonurban	Persistent asthma
Yoos et al. Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. Ann Allergy Asthma Immunol 2002;88(3):283–291. (National Institutes of Health)	Multisite, randomized clinical trial (11 primary care settings)	168 (156 for postintervention, 136 for 1-year interview, 162 for chart review)	**Age** 74% school-aged, 26% adolescent **Gender** 59% male, 41% female **Ethnicity** 66% White 24% Black 10% other **Socioeconomic Status** 51% upper 49% lower **Geographic Location** 34% urban 66% nonurban	

Citation (Sponsor)	Study Design	Study Population		
		Study N (Number Evaluable)	Population Characteristics	Asthma Severity at Baseline (if reported)
Wilson et al. A prospective evaluation of the 1-hour decision point for admission versus discharge in acute asthma. J Intensive Care Med 2003;18(5): 275–285. (Program for Healthcare Innovation, University of Massachusetts Medical Center)	Randomized, double-blind, placebo-controlled trial	50 (50)	**Age** 6–48 yr, mean = 24 yr **Gender** 38% male, 62% female **Smoking** 32% current smokers	Presenting to ED for acute asthma or suspected asthma Duration of asthma, mean = 12 years Duration of symptoms prior to presentation, range 1 to 336 hours, mean = 72 hours
Gorelick et al. Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. Pediatr Emerg Care 2004;20(1): 22–26. (Maternal and Child Health Bureau, Health Resources and Services Administration, DHHS)	Prospective cohort study	456 (292 with attempt at PEF)	**Age** 6–18 yr, mean = 10.1 yr **Ethnicity** 100% White	Presenting at pediatric ED with acute asthma
Vargas et al. Underestimation of the peak flow variability in asthmatic children: evaluation of a new formula. Pediatr Pulmonol 2005;39(4):325–331.	Descriptive	35	**Age** 8–14 yr, mean = 10.7 yr **Gender** 57.1% male, 42.9% female **Height** 115–170 cm, mean = 141.2 cm **Weight** 23 to 88.5 Kg, mean = 44.4 Kg **Body Mass Index** 15.0 to 31.2 Kg/m^2, mean = 21.7 Kg/m^2	Mild intermittent asthma

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
A. Validity/correlation of PEF						
Alcock et al. Symptoms and pulmonary function in asthma. Respir Med 1998;92(6): 849–857. (National Asthma Campaign, GlaxoWellcome, Breathe North and Duncan Flockhart)	**Purpose/Objective:** To examine the relationship between reported symptoms, pulmonary function (expressed as best and actual/best), and therapy		Mean actual/best peak flow varied from 82% for those on oral steroids to 91% for those on low-dose ICS.			Significant correlation between symptoms score and actual function; strongest with FEV_1. Correlation between symptoms and actual/best function; weaker for FEV_1. With PEF relationship with nocturnal disturbance was similar for best (r=0.14) and actual/best (r=0.16). Using quintiles of function, symptoms were less as best function increased, but were greater in the 5th vs. 3rd and 4th quintiles of actual/best FEV_1.
Brand et al. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyper responsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax 1999; 54(2):103–107. (Netherlands' Government Health Research Promotion Programme)	**Purpose/Objective:** To assess the pattern of PEF variation over time and its relationship to changes in other parameters of disease activity		PEF improved during first 2 months for BA+ICS and was unchanged for BA+PL (95% CI for difference 17–77 L/min for morning PEF and 10–71 L/min for afternoon PEF). PEF variation decreased during first 2 months with ICS (95% CI for a difference of 6.6%–20.5%) and then remained stable (95% CI for a difference of 6.2%–19.0%).			For individuals in the BA+ICS group (n=44), positive associations were found between variation in PEF, percentage of symptom-free days, PD_{20} histamine, and FEV_1 % predicted with a wide range of associations.
	Arm 1: Salbutamol 200 mcg + budesonide 200 mcg (BA+ICS) 3 times daily (n not reported; n=44 at 20 months) **Arm 2:** Salbutamol 200 mcg + placebo inhaler 3 times daily (BA+PL) (n not reported)	Every 2 months for 20 months				

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
Eid et al. Can peak expiratory flow predict airflow obstruction in children with asthma? Pediatrics 2000; 105(2):354–358.	**Purpose/Objective:** To examine whether PEF monitoring creates inaccuracies in assessment of children with moderate-to-severe asthma		PEF, FEV_1, and $FEF_{25–75\%}$ correlated ranging from 0.59 to 0.73. PEF, FEV_1, and $FEF_{25–75\%}$ were inversely related to air trapping (RV/TLC). NPV drops for FEV_1 (p=0.02) and for $FEF_{25–75\%}$ (p=0.008) using RV/TLC levels of ≥30 as cutoff. Sensitivity of PEF to detect abnormal pulmonary function was 76% with specificity 77%. Positive predictive value was 81%.			
		214 pulmonary function tests on outpatients for routine asthma monitoring and 153 on inpatients just before hospital discharge				
Goldstein et al. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001; 119(4): 1001–1010. (Asthma Center Education and Research Fund; Merck & Cos., Inc.)	**Purpose/Objective:** To evaluate several PEFvar indexes in a population of patients with suspected asthma and normal spirometry findings and to assess level of compliance in performing 2 to 3 weeks of home peak flow monitoring followed by a methacholine inhalation challenge (MIC)		There were no significant correlations for any of the PEFvar indexes with MICs. Specificity of the period PEFvar indexes ranged from 0 to 93.3%. MIC was the most sensitive test (85.7%) and had best negative predictive value (56.25%). MIC, post-BD FEV_1, and the best mean daily PEFvar index had 100% specificity and 100% positive predicted value.	Greater compliance with MIC as compared with acceptable peak flow diary (66% vs. 50.4%, p=0.012).		
		PEF recorded 4 times daily for 2 to 3 weeks followed by an MIC 28 PEF variation indexes (PEFvar) were computed for each subject				

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
Kamps et al. Peak flow diaries in childhood asthma are unreliable. Thorax 2001; 56(3):180–182.	**Purpose/Objective:** To examine the accuracy and reliability of peak flow diaries in White children with relatively stable asthma			Reported compliance did not differ between BI and EI (96.6% vs. 94.8%). Mean reported compliance was higher than actual compliance (96.6% vs. 73.4% for BI; 94.8% vs. 80.9% for EI) with no difference in actual compliance between BI and EI. There was no difference between groups in percent of correct, incorrect, missing, and self-invented PEF diary entries. Percentage of correct PEF entries decreased throughout the study in both groups. Percentage of self-invented PEF values increased from week 1 to week 4 in BI group (p=0.001), but not in EI group (p=0.28).		
	Arm 1: Basic information (BI) that device allowed for more accurate assessment of peak flow **Arm 2:** Extended information (EI) given basic information plus told that peak flow values would be used in guiding adjustments to treatment	Recorded peak flow measurements in written diary for 4 weeks compared with electronically recorded data for the same period				

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
Leone et al. For Asthma Clinical Research Network of the NHLBI. The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical research. Chest 2001;119(4): 1027–1033. (National Institutes of Health grants)	**Purpose/Objective:** To define the operating characteristics of various self-reported measures of asthma with regard to their ability to identify a fall in FEV_1 of ≥20% from baseline, and to identify the diary-derived measure with the best diagnostic capabilities within each of 3 measurement categories: peak flow, symptom score, and $beta_2$-agonist use		No index of PEF displayed superior discriminative capacity over any other. Changing the cutoff value to increase sensitivity resulted in increased specificity.		Areas under receiver operating characteristic (ROC) curves for tests of exacerbation ranged from 0.51 to 0.79 with no curves attaining both sensitivity and specificity of ≥80% at any cutoff value. Curves within and between groups were similar, regardless of measure employed, period analyzed, or positivity criteria used.	
	Disease-positive group: Treatment failures defined as fall in FEV_1 ≥20% from baseline (n=71) **Disease-negative group:** (n=242)	Subjects recorded disease-related information daily during both source studies.				
Llewellin et al. The relationship between FEV_1 and PEF in the assessment of the severity of airways obstruction. Respirology 2002;7(4): 333–337. (Health Research Council of New Zealand; the Guardian Trust)	**Purpose/Objective:** To compare measurements of FEV_1 and PEF in subjects with either asthma or chronic obstructive pulmonary disease (COPD)		Estimated mean difference (% predicted FEV_1 minus % predicted PEF) was –10.9% (95% CI –12.8% to –8.9%). Limits of agreement from components of variance were –35.4% to 13.6%. FEV_1 % predicted minus PEF % predicted increased as severity of airflow obstruction decreased. Weighted kappa for agreement between category of airway obstruction based on FEV_1 and PEF was 0.59 (95% CI 0.48–0.70). Estimated mean difference of % predicted FEV_1 and PEF was –13.9% (95% CI –11.3 to –16.4) for those with asthma.			
	Subjects drawn from patient files at outpatient chest clinic.					

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
Reddell et al. When can personal best peak flow be determined for asthma action plans? Thorax 2004;59(11): 922–924. (Asthma Foundation of NSW, the National Health and Medical Research Council of Australia, AstraZeneca Sweden and AstraZeneca Australia)	**Purpose/Objective:** To examine the time when personal best PEF stabilizes after initiation of inhaled corticosteroids Data from all subjects were combined for analysis. The rate of change in PEF was calculated as difference between average value for the previous 4 weeks and average for subsequent 4 weeks (2-week periods used for first 4 weeks). Plateau was determined as the week in which pairwise comparisons of 4-week averages with subsequent averages became nonsignificant.		Personal best PEF improved from 484 L/min (87% predicted, 95% CI 82–92) to plateau of 527 L/min (95% predicted, 95% CI 90–100; p<0.0001). Plateau reached after 3 weeks of treatment when reliever use was 0.9 occasions/day (IQR 0.3–2.9). Plateau delayed to 8 weeks if morning PEF values were analyzed. Average morning PEF improved to week 13 (467 L/min, 84% predicted, 95% CI 79–90; p<0.0001 with week 3) and reliever use to week 30 (0.1 occasions/day, IQR 0.0–0.8; p<0.0001 with week 3).			
B. Peak flow versus symptoms in management						
Adams et al. A randomized trial of peak-flow and symptom-based action plans in adults with moderate-to-severe asthma. Respirology 2001; 6(4):297–304. (The University of Adelaide, The Queen Elizabeth Hospital Research Foundation)	**Purpose/Objective:** To compare the effect of PFM-based with symptom-based action plans in adult hospital outpatients with moderate-to-severe asthma who did not have evidence of poor perception of bronchoconstriction **Arm 1:** Written, self-management action plan activated by a decrease in PEF (n=73 in analysis) **Arm 2:** Written, self-management action plan activated by an increase in symptoms (n=61 in analysis) (stratified randomization by age and gender)	Monthly assessment for 12 months	No significant changes in FEV_1 in either group. No difference between groups in PD_{20} histamine.	Appropriate use of action plans was implemented in 85% of symptoms and 86% of PFM exacerbations.	*No differences between groups in health care utilization, ED visits, hospitalizations for asthma, and days absent from school or work due to asthma.	

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
McMullen et al. Peak flow meters in childhood asthma: parent report of use and perceived usefulness. J Pediatr Health Care 2002; 16(2):67–72. (National Institutes of Health grants)	**Purpose/Objective:** To describe reported peak flow monitoring use over time and families' perceptions of its usefulness					At 3 months, 90% of parents perceived benefit in monitoring method; 93% planned to continue with method learned. No difference between groups. 82% of children perceived benefit and 71% continued to use assigned monitoring method: 81% of symptom-monitoring group, 73% of symptom-time PFM vs. 61% of daily PFM (p=0.05). At 1 year, there was no difference between symptom-time and daily PFM users in frequency of PFM use; 75% of school-age children continued use of PFM vs. 44% of adolescents (p=0.01). Children who reported more symptoms reported more frequent use of PFM (r=0.48, p=0.0001).
	Arm 1: Training in monitoring subjective symptoms (symptom monitoring) (n not reported) **Arm 2:** Training in peak flow monitoring at symptomatic times (symptom-time PFM) (n not reported) **Arm 3:** Training in daily and symptom-time peak flow monitoring (daily-PFM) (n not reported)	2-week training period and 3-month postintervention period of diary keeping and telephone contact every 2 weeks; followup contact 1 year after exiting from protocol. Overall 156 (93%) completed protocol; 136 (81%) available for 1 year contact.				

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
Yoos et al. Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. Ann Allergy Asthma Immunol 2002; 88(3):283–291. (National Institutes of Health)	**Purpose/Objective:** To evaluate the effect of 3 different intensities of symptom monitoring on asthma morbidity outcomes		No differences by treatment group in improvement in FEV_1.		*Improvement in composite severity score was greater for symptom-time PFM than for daily PFM (–0.26 vs. –0.10, p=0.002). There was no difference among treatment groups for White children, but among Black children, daily PFM showed improvement in composite severity score vs. symptom-time PFM (p=0.03). There were no differences overall among groups at 1 year, but both PFM groups showed improvement in severity score compared to symptom monitoring group for Black children (p<0.05). Symptom-time PFM group improved in number of symptom days at 3 months vs. symptom-monitoring group (0.87 days/week vs. 0.4 days/week, p=0.01).	There were no differences among groups in the change in health care utilization from pre- to postintervention.
	Arm 1: Training in monitoring subjective symptoms (symptom monitoring) (n=56) **Arm 2:** Training in peak flow monitoring at symptomatic times (symptom-time PFM) (n=55) **Arm 3:** Training in daily and symptom-time peak flow monitoring (daily PFM) (n=57) (stratified randomization based on race, age, and geographic location)	Postintervention assessment at 3 months; postexit interview at 1 year				

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
Wilson et al. A prospective evaluation of the 1-hour decision point for admission versus discharge in acute asthma. J Intensive Care Med 2003; 18(5):275–285. (Program for Healthcare Innovation, University of Massachusetts Medical Center)	**Purpose/Objective:** To evaluate the 1-hour decision point for discharge or admission for acute asthma, to compare the admission recommendations of the Expert Panel Report–1 guidelines, and to develop a model for predicting need for admission in acute asthma		PEFR and FEV_1 correlated throughout the study (r=0.80 at baseline, 0.78 at 1 hours, 0.72 at 2 hours), results were more reproducible using FEV_1. Spirometric measurements differed between those discharged and those admitted/relapsed at baseline and after therapy, with no difference between groups across time. The maximal information content (0.161) occurred at a FEV_1 decision threshold of $\geq$70% of predicted at the 120-minute time point (sensitivity 99%, specificity 41%).		22% were admitted to the hospital with no difference between MDI+S and NEB. There was no difference between those discharged and those who were admitted or had a relapse on baseline characteristics, delivery method in the ED, and serial monitoring of clinical variables during treatment.	Only the ability to lie flat without dyspnea showed a significant difference over time between those discharged and those admitted or relapsed (p=0.0164). The ability to lie flat without dyspnea and the FEV_1 at 60 minutes produced the highest overall classification accuracy of 86% (sensitivity 97.1%, specificity 62.5%). A scoring system using these 2 variables performed better (p=0.0054) than the admission algorithm of the Expert Panel Report–2 guidelines.
	Arm 1: Albuterol by metered-dose inhaler with spacer (MDI+S) at dose of 1 puff of 90 mcg every minute for 4 puffs followed by placebo administered by updraft nebulizer (3.0 mg normal saline) (n not reported) **Arm 2** Propellant gas by inhaler at 1 puff every minute for 4 puffs followed by albuterol sulfate inhalation solution 0.093% by nebulizer (NEB) (n not reported)	Treatment every 20 minutes with a minimum of 3 treatments and a maximum of 6 treatments. After 3 rounds, all received systemic corticosteroid therapy and disposition determination made.				

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
Gorelick et al. Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. Pediatr Emerg Care 2004;20(1):22–26. (Maternal and Child Health Bureau, Health Resources and Services Administration DHHS)	**Purpose/Objective:** To determine the frequency with which children were able to perform PEFR in the context of ED treatment of an acute asthma exacerbation and to identify factors associated with proper performance		*65% with PEFR attempt were able to provide valid reading (95% CI 60%–71%). Patients unable to perform PEFR were younger than those able to perform (8.7 vs. 11.2, 95% CI for diff. 1.8–3.2 yr). Correlation between clinical severity score and inability to perform PEFR at start (r_s=0.52) and end (r_s=0.53) of treatment.	64% had at least 1 attempt at PEFR during the ED visit. Those with no attempt were less likely to be admitted to the hospital than those who did have attempt (18% vs. 33%, p= 0.001). 44% with mild intermittent asthma and 38% of those with persistent asthma did not have PEFR done (p=0.44).		
	Patients were treated using standardized, written management guidelines, based on the recommendations of the National Heart, Lung, and Blood Institute's National Asthma Education and Prevention Program, employing a stepped approach that emphasized aggressive use of inhaled bronchodilators and early use of systemic steroids.					

Citation (Sponsor)	Study Characteristics		Findings			
	Treatment	Assessment/ Off-Treatment Followup	Lung Function	Compliance	Morbidity	Other
Vargas et al. Underestimation of the peak flow variability in asthmatic children: evaluation of a new formula. Pediatr Pulmonol 2005;39(4): 325–331.	**Purpose/Objective:** (1) To evaluate the degree of underestimation of PEF variability in a population of children with asthma in whom circadian changes in PEF measurements were monitored and (2) to assess the accuracy of a new formula based on sinusoidal curve fitting to calculate PEF variability %variability = $200\|PEF_{4pm}-PEF_{10am/pm}\|/ PEF_{10am/pm}$)		PEF varies during 24-hr period, reaching higher values during the day (117.9 $\pm$ 6.8% predicted) and lower during night (108.0 $\pm$ 6.7% predicted, p<0.0001). According to sinusoidal curve fitting, maximal PEF observed at 16 hr 4 min and minimal PEF at 3 hr 20 min.			PEF variability: (1) Actual variability in PEF, median 37.3%, (2) sinusoidal curve fitting, median 21.4% (p<0.05 vs. actual), (3) theoretical, median 17.8% (p<0.01 vs. actual), (4) proposed formula, median 15.9% using 4 p.m. and 10 a.m. and 27.4% using 4 p.m. and 10 p.m. (p<0.01 vs. actual for both), and (5) 3 examples ranged from 4% to 8.7% (p<0.01 vs. actual in both cases). Correlation with actual PEF variability: sinusoidal curve fitting, r_c=0.79; usual formula, r_c=0.67; proposed formula, r_c=0.68; 3 examples, r_c =0.18 to r_c=0.38.
	PEF measurements taken at different hours of the day or night until a total of 12 measurements at 2-hour intervals covering a 24-hour period at even hours. Children were allowed to accomplish the 12 PEF measurements in a full week. Personal peak flow meters with less than 3 months' utilization were used. Variability calculated using 5 methods: (1) actual variability, (2) sinusoidal curve variability, (3) theoretical greatest variability, (4) proposed formula variability using values obtained at 4 p.m. and either 10 a.m. or 10 p.m., and (5) examples of variability using traditional formula.					